Vertex Pharmaceuticals (NASDAQ: VRTX) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Vertex Pharmaceuticals to related businesses based on the strength of its earnings, dividends, valuation, institutional ownership, analyst recommendations, risk and profitability.
This is a summary of current ratings and price targets for Vertex Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vertex Pharmaceuticals Competitors||1134||3423||11925||240||2.67|
Vertex Pharmaceuticals presently has a consensus price target of $175.75, indicating a potential upside of 11.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.21%. Given Vertex Pharmaceuticals’ rivals higher possible upside, analysts plainly believe Vertex Pharmaceuticals has less favorable growth aspects than its rivals.
Volatility & Risk
Vertex Pharmaceuticals has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals’ rivals have a beta of 1.25, meaning that their average share price is 25% more volatile than the S&P 500.
Valuation & Earnings
This table compares Vertex Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Vertex Pharmaceuticals||$1.70 billion||-$112.05 million||202.47|
|Vertex Pharmaceuticals Competitors||$290.27 million||$35.99 million||55.79|
Vertex Pharmaceuticals has higher revenue, but lower earnings than its rivals. Vertex Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
93.1% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 1.8% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Vertex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vertex Pharmaceuticals Competitors||-6,483.92%||-160.78%||-34.99%|
Vertex Pharmaceuticals beats its rivals on 9 of the 13 factors compared.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company’s marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company’s development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.